Straight from Benzinga newsdesk, host Brent Slava brings you the market news and stocks to watch.

Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659

Hosts:

Brent Slava Reach out to Brent at [email protected]

Sr. Reporter, Head of Benzinga Newsdesk

Michael O'Connor Reach out to Michael at [email protected]

Benzinga Strategy Development

pro.benzinga.com

• Zoom Video Communications (ZM) - Potentially next week's most exciting earnings report (maybe that's not saying a lot). Zoom will report quarterly results on Monday morning.
• Boston Beer (SAM) - The owner of alcoholic beverage brands including Sam Adams, Twisted Tea, Truly and Dogfish Head. The company was the subject of an interesting analyst research report Friday. Analysts at Morgan Stanley responded to pushback following their setting of a new Underweight rating and $300 price target on the stock last week. In the note Friday morning, the analysts showed conviction in their belief that certain Boston Beer brands "holding [market] share looks challenging" amid current competition.
• Provention Bio (PRVB) - Friday morning's most-discussed stock in the Benzinga Pro lounge chat. The stock was down about 10% following news the company's drug to delay the onset of Stage 3 Type 1 diabetes was the first candidate to win FDA approval. Traders in the Benzinga Pro chat showed concern with the Provention drug's cost and seemingly intensive administration.
• Fulgent Genetics (FLGT) - Analysts at Raymond James initiated coverage on the stock with the firm's equivalent of a buy rating. The analysts said Fulgent "capitalized on COVID-19 testing capabilities...and has now deployed part of their substantial cash hoard to emerge from the pandemic with the full breadth of oncology testing capabilities."
• Steakholder Foods (STKH) - A technology company in the food space. The company is developing a 3D bioprinting technology in order to effectively build edible meat cultures without slaughtering animals. Shares of this low-float name were up 20% in pre-market action following a company press release which highlighted news of a competitor in its space winning FDA approval for a similar process Steakholder is developing.

We're always looking for ways to make this content better!If you have ideas for stocks we should cover or have feedback about the info or presentation, please drop us a line at [email protected] or [email protected]

Use coupon code YOUTUBE20 to get 20% off

Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy